Home Press Releases The American College of Chest Physicians updates their antithrombotic therapy guidelines for patients with atrial fibrillation

The American College of Chest Physicians updates their antithrombotic therapy guidelines for patients with atrial fibrillation

Glenview, Ill. – The American College of Chest Physicians® (CHEST) announced updates to the evidence-based guidelines on antithrombotic therapy for atrial fibrillation. Atrial fibrillation is the most common sustained cardiac arrhythmia with an increase in prevalence and incidence with age. In adults over the age of 40, there is a one in four lifetime risk of developing atrial fibrillation. Many of the risk factors leading to incident atrial fibrillation are also risk factors for ischemic stroke. The promotion of an integrated or holistic approach for atrial fibrillation management is needed, incorporating stroke prevention, addressing symptoms and managing risk factors.

The guideline panel submitted the manuscript, Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report, for publication in the journal CHEST®.

“Incorporating stroke prevention and addressing risk factors are essential in providing the best care for patients,” says Editor in Chief of the journal CHEST Richard S. Irwin, MD, Master FCCP. “These guidelines reflect the most up-to-date clinical research since the last publication in 2012.”

Key recommendations and shifts from previous guidelines include:

  • For patients with atrial fibrillation without valvular heart disease, including those with paroxysmal atrial fibrillation who are at low risk of stroke (eg, CHA2DS2VASc score of 0 in males or 1 in females), we suggest no antithrombotic therapy.
  • For patients with a single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel.
  • For those at high risk of stroke, we recommend oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel.
  • Where we recommend or suggest in favor of oral anticoagulation, we suggest using a novel oral anticoagulant (NOAC) rather than adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a time in therapeutic range (TTR) >70%.
  • Attention to modifiable bleeding risk factors should be made at each patient contact, and HAS-BLED score should be used to assess the risk of bleeding where high-risk patients (>=3) can be identified for earlier review and follow-up visits.

“Understanding the most up-to-date clinical research assists medical professionals in providing the best quality of care for their patients,” says President of the CHEST Foundation Lisa K. Moores, MD, FCCP, and a member of CHEST’s Guidelines Oversight Committee. “It is essential that these guidelines are shared with medical professionals and understood by their patients as well.”

The complete guideline article is free to view in the Online First section of the journal CHEST.

About CHEST Living Guidelines 

Living guidelines are systematically developed, evidence based and continually updated recommendations for the diagnosis and management of medical conditions. These guidelines are intended to inform both health-care providers and patients in making educated clinical decisions.

About the American College of Chest Physicians®

CHEST is the global leader in prevention, diagnosis and treatment of chest diseases. Its mission is to champion advanced clinical practice, education communication and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST®, visit chestnet.org.